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Glutaminase (GA) catalyzes the first step in mitochondrial glutaminolysis playing a key role in cancer 
metabolic reprogramming. Humans express two types of GA isoforms: GLS and GLS2. GLS isozymes 
have been consistently related to cell proliferation, but the role of GLS2 in cancer remains poorly 
understood. GLS2 is repressed in many tumor cells and a better understanding of its function in 
tumorigenesis may further the development of new therapeutic approaches. We analyzed GLS2 
expression in HCC, GBM and neuroblastoma cells, as well as in monkey COS-7 cells. We studied GLS2 
expression after induction of differentiation with phorbol ester (PMA) and transduction with the full-
length cDNA of GLS2. In parallel, we investigated cell cycle progression and levels of p53, p21 and c-Myc 
proteins. Using the baculovirus system, human GLS2 protein was overexpressed, purified and analyzed 
for posttranslational modifications employing a proteomics LC-MS/MS platform. We have demonstrated 
a dual targeting of GLS2 in human cancer cells. Immunocytochemistry and subcellular fractionation 
gave consistent results demonstrating nuclear and mitochondrial locations, with the latter being 
predominant. Nuclear targeting was confirmed in cancer cells overexpressing c-Myc- and GFP-tagged 
GLS2 proteins. We assessed the subnuclear location finding a widespread distribution of GLS2 in the 
nucleoplasm without clear overlapping with specific nuclear substructures. GLS2 expression and nuclear 
accrual notably increased by treatment of SH-SY5Y cells with PMA and it correlated with cell cycle arrest 
at G2/M, upregulation of tumor suppressor p53 and p21 protein. A similar response was obtained by 
overexpression of GLS2 in T98G glioma cells, including downregulation of oncogene c-Myc. Furthermore, 
human GLS2 was identified as being hypusinated by MS analysis, a posttranslational modification 
which may be relevant for its nuclear targeting and/or function. Our studies provide evidence for a tumor 
suppressor role of GLS2 in certain types of cancer. The data imply that GLS2 can be regarded as a highly 
mobile and multilocalizing protein translocated to both mitochondria and nuclei. Upregulation of GLS2 
in cancer cells induced an antiproliferative response with cell cycle arrest at the G2/M phase.
Altered metabolism is a hallmark of cancer1 and the term “metabolic reprogramming” has been coined to 
describe the whole range of metabolic abnormalities accompanying tumorigenesis and metastasis2. Increased 
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glutamine (Gln) uptake and glutaminolysis are key metabolic traits that have been consistently found in a wide 
range of human and experimental cancers3. The term “Gln addiction” is now widely used to reflect the strong 
dependence shown by most cancer cells for this essential nitrogen substrate after metabolic reprogramming4. 
Glutaminase (GA, EC 3.5.1.2) proteins control the first step in the glutaminolytic process: the conversion of Gln 
to glutamate (Glu) and ammonium ions5. In mammals, four different isoenzymes have been characterized so far:6 
the alternative spliced KGA and GAC proteins, encoded by the Gls gene7,8, and the LGA and GAB isoforms coded 
by the second GA gene, Gls29. The GAB isozyme is the product of the canonical full-length transcript coded by 
the Gls2 gene10, while the short LGA transcript appears by alternative transcription initiation and uses an alter-
native promoter11.
It is well documented that many tumors show increased GA activity which is positively correlated with their 
malignancy3. GA and glutaminolysis play key roles in tumorigenesis which are not only related to energy gen-
eration, but also with the supply of nitrogen and carbon skeletons for macromolecule biosynthesis12. We ini-
tially reported that inhibition by antisense technology of Gls expression (KGA isoform) allowed the reversion of 
Ehrlich ascites tumor cells to a more differentiated and less malignant phenotype13. Recent works are starting to 
uncover the differential expression of GA isoenzymes in cancer, along with their regulation by oncogenes and 
tumor suppressor genes. Thus, it has been shown that oncogene c-Myc derepresses GLS expression in several can-
cer cell types through a miRNA mechanism14. GLS isoforms are also upregulated by certain oncogenic signaling 
pathways, such as the small Rho GTPases15, which activate the GLS isoform GAC through a mechanism depend-
ent on nuclear factor-kappa B (NF-κB)16. Hence, the link between GLS isoforms and neoplastic transformation 
seems supported by convincing evidence in human gliomas, lung and liver tumors.
While GLS upregulation correlates with proliferating stages and malignancy in many types of cancer and 
experimental tumors, little is known about the role of GLS2 in tumorigenesis. We first postulated a completely 
different role for GLS and GLS2 isoforms in cancer based on their relative expression patterns in human leu-
kemia, breast cancer cells, and hepatocellular transformation17. The process of malignant transformation shifts 
the pattern of GA expression in such a way that GLS becomes upregulated while GLS2 is frequently repressed; for 
instance, transformed liver cells, like HepG2, return to a fetal-like phenotype, characterized by a high rate of cell 
proliferation and prevalence of GLS isoforms over GLS2 ones, which predominate in normal nonproliferating 
hepatocytes17. Co-expression of GLS and GLS2 transcripts has been reported in established cancer cell lines of 
colon, hepatoma, leukemia and breast, although protein data suggest that GLS isoforms would account for the 
majority of GA activity in these human tumor cells17,18. In fact, GLS2 expression is repressed in highly malignant 
glioblastoma (GBM)19, as well as in human liver and colon cancers20–22. Furthermore, GLS2 was confirmed as a 
target gene of the tumor suppressor p53, in such a way that p53-controlled enhanced GLS2 expression was linked 
to a tumor-suppressive response, including reduced growth and colony formation of tumor cells20,21. Importantly, 
a recent study implicated GLS2 in miRNA regulation through Dicer stabilization, upregulation of miR-34a and 
repression of Snail and metastasis in hepatocellular carcinoma (HCC) cells23. Therefore, a strikingly different pat-
tern, opposed to GLS, is becoming evident for GLS2 in many malignancies, but not all3. In this work, we extended 
our previous finding of a nuclear expression for GLS2 in brain cells24,25 by showing that GLS2 is located in both 
mitochondria and nuclei of human cancer cells. GLS2 overexpression elicits an antiproliferative response involv-
ing mitochondria and cell nucleus; the nuclear targeting correlated with a p53-dependent tumor suppressive 
mechanism allowing proliferation arrest of human cancer cells at G2/M. Thus, overexpression or derepression of 
GLS2 appears as a potential novel therapeutic strategy for certain types of cancer.
Results
Intracellular distribution of GLS2 in human tumor cells. Although a nucleocytoplasmic location for 
GLS2 protein was reported in mammalian brain cells24,25, the subcellular localization of GLS2 in human cancer 
cells has not been yet elucidated. Immunocytochemistry studies in HepG2 human cancer cells using affinity-pu-
rified isoform-specific anti-GLS2 antibodies revealed a cytosolic punctate immunostaining for GLS2, strongly 
suggestive of mitochondrial localization, along with a minor nuclear immunostaining only found in a discrete 
cell population (Fig. 1-A1). Similar results were obtained with T98G and SH-SY5Y human cancer cells (results 
not shown). Accordingly, the minor nuclear mark was also confirmed using double fluorescence labeling with 
anti-GLS2 antibodies and cell nuclei stained with DAPI: only a discrete number of HepG2 cells (19.3%) showed 
GLS2-reactive nuclei (Fig. 1-A3/A4,1B). The mitochondrial mark was further confirmed by double immunoflu-
orescence studies, using cytochrome c as a mitochondrial marker: essentially most of the extranuclear cytosolic 
GLS2 staining overlapped with the mitochondrial marker (Fig. 1-A2/A4).
Mitochondria is the default and basal location of GA isoenzymes in mammalian tissues and cells under 
physiological conditions5,6, although previous immunofluorescence microscopy and biochemical data demon-
strated nuclear localization of GLS2 in neurons and astrocytes24,25. To confirm the presence of GLS2 protein in 
the nucleus of human cancer cell lines, HepG2 cells were fractionated into nuclear and cytosolic pools. Then, 
they were probed by Western blot using isoform-specific anti-GLS2 antibodies: the presence of GLS2 proteins in 
both fractions was detected (Fig. 1C). On the other hand, no GLS isoforms were detected by Western blot in the 
assayed nuclear fractions (results not shown), which were devoid of any significant cytoplasmic or mitochondrial 
contaminations as revealed by probing the blots with anti-α-tubulin and anti-cytochrome c oxidase (complex IV) 
specific antibodies (Fig. 1C).
Nuclear localization of GLS2 in human cancer cells transduced with GLS2-tagged constructs. 
To unambiguously demonstrate nuclear targeting of GLS2 proteins in human cancer cells, we decided to use 
orthogonal methods not relying on the recognition of proteins by anti-GLS2 antibodies. Expression constructs 
were prepared with the whole ORF of GLS2 fused to a c-Myc epitope tag or to EGFP fluorescent protein. After 
transfection in SH-SY5Y and HepG2 cells, ectopically expressed GLS2-tagged proteins were visualized either by 
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fluorescence and confocal microscopy or by Western blots of nuclear extracts probed with anti-c-Myc antibod-
ies (Fig. 2). The overexpressed GFP protein control labeled all the cell body (Fig. 2A-I), because GFP can travel 
in and out of the nucleus by passive diffusion due to its small size26. Neuroblastoma SH-SY5Y cells expressing 
GFP-tagged GLS2 showed a fluorescent pattern labeling the cell body, as expected from proteins which are 
co-expressed in mitochondria and nuclei, although some cells showed a predominant nuclear fluorescence 
(Fig. 2A-II). Even more, a few individual cells displayed only the nuclear GLS2 mark without appreciable cytosolic 
labeling (Fig. 2A-III/IV). Many SH-SY5Y cells were not transfected with the EGFP-GAB plasmid, a result that 
would be anticipated taking into account their known resistance to cellular transfection (ThermoFisher Scientific 
technical note, https://www.thermofisher.com/). The nuclear and cytosolic (mitochondrial) localizations of GLS2 
were also revealed in cancer cells transfected with the c-Myc-tagged GLS2 constructs: Western blots of trans-
fected SH-SY5Y and HepG2 cells showed a clear band in both compartments at the expected molecular mass of 
taggeg-GLS2 (Fig. 2C). The protein band corresponding to the endogenous c-Myc protein was also detected in 
most lanes probed with the c-Myc specific antibody (Fig. 2C).
Additionally, we asked whether GLS2 would be also targeted to the nucleus in a cell type with null expres-
sion of this isoform. To answer this question, we chose COS-7 cells that do not have appreciable GLS2 pro-
tein expression, but display a good level of expression after transfection with a pcDNA3-GLS2 vector (Fig. 2-D). 
Then, COS-7 cells were transfected with a pEGFP-GLS2 plasmid and the fluorescent fusion protein visualized 
Figure 1. Intracellular localization of GLS2 in human HCC cells. Immunocytochemistry of HepG2 cells using 
affinity-purified isoform-specific anti-GLS2 antibodies revealed a major cytosolic punctate immunostaining for 
GLS2 and a minor nuclear immunostaining (A1, GLS2). The mitochondrial GLS2 mark was further confirmed 
by double immunofluorescence studies, using cytochrome c as a mitochondrial marker: essentially most of the 
extranuclear cytosolic GLS2 staining overlapped with the mitochondrial marker (A2, Cyt C). Cell nuclei were 
stained with DAPI (A3, DAPI) and the co-localization of GLS2-cyt c and GLS2-DAPI was also revealed using a 
triple overlay (A4, Merge). (B) The minor nuclear mark was also confirmed using double immunofluorescence 
labeling with anti-GLS2 antibodies (green) and cell nuclei stained with DAPI (blue): only a discrete number 
of HepG2 cells showed GLS2-reactive nuclei (19.3%, n = 352 individual cells). (C) Confirmation of the 
nuclear GLS2 mark by subcellular fractionation: nuclear and cytosolic fractions isolated from HepG2 cells 
were probed with anti-GLS2 antibodies by immunoblot analysis (bands cropped from the original Western 
blot shown in Supplemental Fig. S1). The molecular mass of the standard BSA protein marker is indicated 
on the left. Antibodies against TATA-binding protein (TBP), α-tubulin and COX IV were used as organelle 
markers for nucleus, cytoplasm and mitochondria, respectively. NUC, nuclear fractions; CYT/MIT, cytosolic 
(mitochondrial) fractions.
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Figure 2. Nuclear location of GLS2-tagged proteins ectopically expressed in human cancer and COS-7 cells. 
The full-length ORF of GLS2 was cloned in the pCMV-Myc and pEGFP expression vectors. (A) SH-SY5Y 
cells were transfected with pEGFP-GLS2 and GLS2-tagged proteins visualized by fluorescence (A-I, A-II) and 
confocal laser scanning microscopy (A-III, A-IV). The construct pEGFP-24, expressing the GFP protein alone, 
was employed as transfection control for these experiments (A–I). Approximately, 40% of transfected cells 
showed nuclear GLS2 (n = 200). Transfections of transformed African green monkey kidney fibroblast (COS-7) 
cells were done with two expression vectors: pEGFP-GLS2 (B) and pcDNA3-GLS2 (D) which yield the full-
length GLS2 isoform EGFP-tagged and untagged, respectively. EGFP-tagged GLS2 proteins were visualized by 
confocal microscopy after immunostaining with anti-cyt c antibodies to label mitochondria and DAPI staining 
for cell nuclei (B). SH-SY5Y and HepG2 cells were transfected with the plasmids p-CMV-Myc and p-CMV-
Myc-GLS2 (C). Then, nuclear (NUC) and cytoplasmic/mitochondrial (CYT/MIT) fractions were isolated and 
Myc-tagged GLS2 proteins detected by Western blots probed with anti-c-Myc tag antibodies (bands cropped 
and grouped from the original Western blots shown in Supplemental Fig. S1). The construct pCMV-Myc was 
employed as transfection control for Western blotting experiments. Antibodies against TATA-binding protein 
(TBP), α-tubulin and COX IV were used as organelle markers for nucleus, cytoplasm and mitochondria, 
respectively. (D) left lane, wild-type COS-7 cells do not express any appreciable GLS2 proteins; right lane, a clear 
protein band was detected after transfection with pcDNA3-GLS2 construct (full-length original Western blot 
shown in Fig. S1). Both lanes were also revealed with antibodies against β-actin as loading control.
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Figure 3. Differentiation agent PMA increases mitochondrial and nuclear GLS2 protein levels in SH-SY5Y 
and HepG2 cancer cells. (A) Representative Western blot of nuclear fractions isolated from SH-SY5Y cells 
after incubation with 1 µM PMA for 12 h and 24 h or dimethyl sulfoxide (DMSO). Blots were probed with 
antibodies against GLS2, p21, p53 and TATA-binding protein (TBP) used as a loading control. Antibodies 
against COX IV were used to assess cytoplasmic (mitochondrial) contamination. (B) Representative Western 
blot of nuclear fractions isolated from human GBM T98G cells: wild-type (WT), stably-transfected with 
vector alone (pcDNA3) and stably-transfected with GLS2 (GAB). Blots were probed with antibodies against 
GLS2, p53, c-Myc and the loading control TBP. Antibodies against COX IV were used to assess cytoplasmic 
(mitochondrial) contamination. (C) Representative Western blot of whole cellular extracts isolated from 
human GBM T98G cells: wild-type (WT) and stably-transfected with GLS2 (GAB). Blots were probed with 
antibodies against p53 and c-Myc using β-actin as loading control. (D) Confocal microscopy images of GLS2 
immunofluorescence in HepG2 cells treated with PMA. Cells grown on cover slips were treated with vehicle 
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by confocal microscopy. Ectopic expression of GFP-GLS2 in COS-7 labeled the cell body showing an abundant 
punctate cytosolic mark, along with a clear nuclear fluorescent staining (50,7% of transfected cells showed a 
clear nuclear mark, n = 182 individual cells) (Fig. 2B). Some DAPI-stained nuclei (dark blue) appear green and 
greenish-blue due to the intense GFP-tagged GLS2 mark (Fig. 2B-I and II). On the other hand, cytoplasmic 
GLS2 label partially overlapped with the mitochondrial marker (cyt c), giving rise to an orange-yellowish stain 
(Fig. 2B-I and III), although part of the cytosolic GFP-tagged GLS2 proteins did not merge with cyt c (Fig. 2B-I 
and III). Image J analysis of co-localizations yielded Pearson correlation values of pixel intensities of 0.29 and 0.35 
for the EGFP-GLS2/DAPI and EGFP-GLS2/cyt c pairs, respectively (Fig. S2).
Therefore, we conclude that GLS2 protein can be shuttled to the nucleus after ectopic expression in human 
cancer cells; even more, GLS2 protein expressed in cell types with null GLS2 expression (COS-7) was also able to 
be targeted to the cell nuclei.
Differentiation agents induce translocation of GLS2 into cancer cells nuclei. SH-SY5Y and 
HepG2 cells treated with the differentiation agent phorbol 12-myristate 13-acetate (PMA) showed an increased 
nuclear accrual of GLS2 above the basal level observed in untreated cells (Figs. 3-A and 3-D, respectively). This 
enhanced expression was seen at early incubation times for neuroblastoma cells (12–24 h, Fig. 3-A) and HepG2 
cells (6–24 h, Fig. 3-D). The increase of GLS2 expression after PMA stimulation was detected in both mitochon-
dria and nucleus; thus, the Pearson correlation coefficient values for co-localization, obtained after quantification 
of cytoplasmic and nuclear immunofluorescence signals of GLS2, cyt c and DAPI staining in individual HepG2 
cells (n > 75 per condition), significantly increased in PMA-treated cells: from 0.69 to 0.77 for GLS2-DAPI 
(p < 0.0001) and from 0.65 to 0.71 for GLS2-cyt c (p < 0.0001) (Fig. S3). Indeed, the number of cells with nuclear 
GLS2 showed a fourfold rise in the presence of PMA, raising from 19.3% under control conditions (n = 352 cells) 
to 85.5% in cells exposed to PMA (n = 159 cells).
Furthermore, SH-SY5Y cells forced to differentiate with PMA also showed increased protein levels of active 
p53 and its related partner cyclin-dependent kinase inhibitor p21 (Fig. 3-A): the upregulation of p53 and p21 pos-
itively correlated with that of GLS2 in cell nuclei of SH-SY5Y cells treated with PMA for 12 h and 24 h (Fig. 3-A). 
This result associates nuclear translocation of GLS2 with stimulus-inducing differentiation of cancer cells, rein-
forcing the view of GLS2 upregulation as a hallmark of quiescent differentiated cell states, but in sharp con-
trast to the opposite oncogenic role played by GLS isoenzymes17. In addition to cancer cells treated with PMA, 
another model with increased nuclear levels of GLS2 is the GBM cell line T98G-GAB, stably transfected with the 
full-length ORF of GLS2, which possesses a less-malignant phenotype compared with the wild-type T98G paren-
tal cell line27 (Fig. S4). The nuclear extracts of these more differentiated and slow-growing GBM cells showed 
enhanced levels of GLS2 (Fig. 3-B), in agreement with the results previously seen in PMA-treated cancer cells. We 
further assessed the expression levels of the tumor suppressor gene p53 and oncogene c-Myc in T98G-GAB cells 
versus their wild-type T98G counterparts. The immunoblot analysis showed an enhanced p53 expression in both 
nuclear fractions (Fig. 3-B) and whole cellular extracts (Fig. 3-C), while the oncogenic protein c-Myc was also 
down-regulated but only in cellular extracts (Fig. 3-C).
Subnuclear location of GLS2 in tumor cells. To get a deep insight into the nuclear function of GLS2 
we next addressed its subnuclear localization: adscription of the GLS2 mark to a specific subnuclear organelle 
may give us a clue of its potential nuclear function(s). We used two models with an enhanced nuclear targeting 
of GLS2: HepG2 cells stimulated with PMA and T98G-GAB cells overexpressing GLS2. We performed double 
immunofluorescence labeling and confocal microscopy with affinity-purified isoform-specific anti-GLS2 anti-
bodies, along with commercial antibodies specific for two subnuclear organelles: nuclear speckles (Fig. 4-A) and 
nucleoli (Fig. 4-B). The choice of these particular organelles was because the nuclear labeling pattern revealed for 
GLS2 sometimes showed a condensed appearance resembling the topography of these organelles. The confocal 
microscopy results indicated that GLS2 was not exclusively associated with nuclear speckles (although some over-
lapping was detected, Fig. 4-A) or cell nucleolus (Fig. 4-B), but was instead spread around the nucleoplasm. To 
confirm this widespread mark in the nucleoplasm, we also used a third nuclear antibody raised against histone H1 
demethylase as a marker of the nucleoplasm (Fig. 4-C). The GLS2 mark was distributed along the nucleoplasm, 
mimicking the nuclear pattern observed for the histone H1 demethylase protein (Fig. 4-C), without clear segre-
gation or overlapping with known subnuclear structures (Figs. 4-A and 4-B). Quantification of co-localization 
data for GLS2 in subnuclear compartments by analysis of cell nuclei yielded very low Pearson correlation coeffi-
cients (Fig. S5), confirming a widespread nucleoplasmic location of GLS2 without significant co-localization with 
speckles or nucleolus.
DMSO (I–III) or 1 µM PMA in DMSO (II–IV) for 6 h. After incubation, cells were stained with rabbit antibody 
to GLS2 and Alexa 488 conjugated secondary antibody. Induction of differentiation (II–IV) clearly increased 
the nuclear (asterisk) and cytoplasmic accumulation of GLS2 protein (arrows) versus untreated cells (I-III). 
GLS2 also showed some minor nuclear localization without treatment (asterisk in III). Open arrows in IV 
indicate an intense perinuclear immunostaining of GLS2. Scale bars: 100 μm (I,II) and 10 μm (III, IV). Original 
Western blots of Fig. 3-A, B and C are shown in Supplemental Fig. S1. Densitometric analysis of the protein 
bands, normalized to the loading control, are shown on the right of panels A, B and C. For all panels, the values 
represent the mean (n ≥ 2) and the error bars represent ± SD, except for p21 in A and c-Myc in B (n = 1). Paired 
Student’s t test was done between PMA treated and untreated cells, and T98G-GAB vs T98G-WT or T98G-
pcDNA3.*p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001.
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On the other hand, in PMA-treated HepG2 cells a strong perinuclear immunostaining was clearly visible 
(Fig. 3-D). This may suggest that nuclear import of GLS2 could be mediated by a previous mobilization of mito-
chondria around the cell nucleus and hence being imported into the nucleus. Alternatively, the perinuclear ring 
detected in PMA-stimulated HepG2 cells could arise due to a mobilization of vesicles carrying their protein 
cargo toward the nucleus. To assess this latter alternative, we next performed double immunolabeling combining 
anti-vesicle-associated membrane protein 8 (VAMP 8) antibodies, chosen as a marker of traffic vesicles, with 
anti-GLS2 antibodies (Fig. 4-D). The confocal microscopy results showed an intense perinuclear region where 
VAMP 8 and GLS2 immunostainings clearly overlapped in PMA-treated HepG2 cells (Fig. 4-D). The perinuclear 
space appears crowded with vesicles, in coincidence with the perinuclear mark detected for GLS2 protein; hence, 
vesicle-mediated nuclear import of GLS2 in PMA-treated cells cannot be discarded.
Figure 4. Subnuclear localization of GLS2. Confocal microscopy of HepG2 cells treated with PMA. (A) 
GLS2-Nuclear speckles. Double immunofluorescence labeling with anti-GLS2 antibodies (left, green) and 
anti-nuclear speckles antibodies (center, red); right, view of double labeled cells showing only a few overlapping 
spots between the two immunolabels. (B) GLS2-Nucleolus. Double immunofluorescence labeling with anti-
GLS2 antibodies (left, green) and antibodies against fibrillarin specific for cell nucleoli (center, red); right, 
merge view of double labeled cells: the nucleolar marker did not overlap with the nuclear GLS2 mark. (C) 
GLS2-Nucleoplasm. Confocal microscopy of HepG2 cells treated with PMA after double fluorescence labeling 
with anti-GLS2 antibodies (left, green) and anti-JMJD5 histone demethylase antibodies, a marker specific for 
cell nucleoplasm (center, red). (D) Double immunofluorescence labeling and confocal microscopy of HepG2 
cell employing anti-VAMP8 (green) and anti-GLS2 (red) antibodies: the merge panel shows a high degree of 
overlapping marks.
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Increases in the nuclear and mitochondrial accrual of GLS2 protein associate with G2/M cell 
cycle stage. Next, we aimed to ascertain whether tumor cells overexpressing GLS2 constitutively (T98G-GAB) 
or after induction of differentiation by PMA treatment (SH-SY5Y) shift their cellular populations toward cell 
cycle stages compatible with lower proliferation. First, we determine the growth curves for glioma cell lines 
T98G-WT, T98G-pcDNA3 (sham-transfected) and T98G-GAB. Glioma cells overexpressing GAB decrease their 
proliferation (Fig. 5A) vs wild-type and sham-transfected controls, a result previously reported by our group27. 
For example, mean doubling times were 1,824 ± 0,034 for GAB-transfected cells vs 1,188 ± 0,039 for the WT 
counterparts (Fig. S4A). Then, we performed a cell cycle analysis to detect shifts in the distribution of cancer cells 
after GLS2 overexpression. A clear trend was revealed in T98G-GAB cells: a strong increase in the population of 
cells in the G2/M phase, along with a decrease in S and G0/G1 stages, was detected as compared with WT and 
sham-transfected cell counterparts (Fig. 5B). For SH-SY5Y neuroblastoma cells, differentiation agent PMA also 
induced a clear inhibition of cell proliferation with cell numbers half of those shown by DMSO-treated control 
cells (Fig. 5C). Moreover, DNA flow cytometric analysis of neuroblastoma SH-SY5Y cells indicated that treat-
ment with PMA also resulted in a G2/M arrest, when compared with control untreated cells (Fig. 5D). Thus, two 
cancer cell models with increased GLS2 expression and nuclear accrual showed a stabilization of the cell cycle in 
Figure 5. Cell cycle studies in human GBM T98G-GAB cells and human neuroblastoma SH-SY5Y cells treated 
with PMA for 24 h. (A) For assessing the effect of GAB overexpression on cell proliferation, 8 × 104 T98G, 
sham-transfected T98G-pcDNA3 and GAB overexpressing T98G-GAB(+) cells were seeded per well in 6-well 
plates. Cells were detached and counted in triplicate (independent wells) at days 1, 2, 3, 4 and 5 after seeding. 
Cell number was normalized to the value at day 1 for each cell line variant assayed. (B) FACS sorting of T98G, 
T98G-pcDNA3 and T98G-GAB cells after 24 hours in culture. The chart indicates the percentage of total cells 
found at each cell cycle stage. Wild-type T98G cells and cell lines stably transfected with the full-length ORF 
of GLS2 (T98G-GAB) and vector pcDNA3 alone (T98G-pcDNA3) were analyzed. (C) For assessing the effect 
of PMA on cell proliferation rate, 1 million SH-SY5Y cells were seeded per well in eight 6-well plates. After 
24 hours, once cells were just attached to the surface, cell culture medium was supplemented with 1 µM PMA 
dissolved in DMSO (experimental group) or 0.033% DMSO for the control group (same DMSO concentration 
than the experimental group). Cells were detached and counted in quadruplicate (independent wells) at days 1, 
3, 5 and 7 after treatment. (D) FACS sorting of SH-SY5Y control cells (DMSO) and SH-SY5Y cells treated with 
PMA after 24 hours in culture. The chart indicates the percentage of total cells found at each cell cycle stage. 
Three distinct samples were analyzed for each independent human cancer cell line assayed. Panel B (ANOVA): 
**p < 0.01; ***p < 0.001; ****p < 0.0001. Panel D (Student’s t test): **p < 0.01.
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the G2/M phase, in sharp contrast with GLS isoforms whose expression was upregulated in G1 and S phases in 
association with cell proliferation28.
Posttranslational modification of human GLS2 protein. Finally, we set up a baculovirus expression 
system and affinity purification to obtain functional human GLS2 for analysis of posttranslational modifications29. 
The human GLS2 protein was purified by affinity chromatography employing the Glutaminase-Interacting 
Protein (GIP) as a specific ligand (Fig. S7). The purified GLS2 fractions were digested with trypsin and chymo-
trypsin and then submitted to LC-MS/MS analysis. Higher energy collision dissociation (HCD) allowed better 
sequence coverage than collision-induced dissociation (CID) with both proteolytic enzymes, ranging from 57.6% 
to 77.1%, while the number of unique GLS2 peptides identified was slightly higher for the chymotrypsin digestion 
Figure 6. Posttranslational modification of recombinant human GLS2 protein with acetylhypusine. 
(A) Representative spectrum of a GLS2 peptide with acetylhypusine modification. The peptide 
KEKKCFPKGVDMMAAL (from amino acid 329 to 344 of the GLS2 sequence) appears as a charge + 3 peptide 
with a monoisotopic m/z of 661.34753 Da (+0.29 mmu/+0.44 ppm). MH: 1982.02805 Da, including C-5 
carbamidomethyl (57.02 Da), M-12 oxidation (15.99 Da) and K4-Acetylhypusine (113.08 Da). (B) Validation 
of GLS2 hypusination by immunoblot analysis using specific rabbit polyclonal anti-hypusine antibodies. Four 
different fractions containing affinity-purified recombinant human GLS2 from two different GIP-affinity 
purifications were analyzed. The anti-hypusine antibodies recognized a band in all four lanes corresponding 
to the known molecular mass of mature GLS2 protein (29). Electrophoresis was done in 12% polyacrylamide 
Bis-Tris gel with PageRuler Prestained Protein Ladders (Thermo Scientific) (positions of markers indicated at 
the right end). (C) Positive and negative controls for hypusination. A whole protein extract from mouse brain 
and rat prefrontal cortex (20 µg each) were employed as positive controls by revealing a band of the hypusinated 
eIF5A protein at approx. 17 kDa (lanes 1 and 2). Purified human recombinant GLS256–602 protein expressed 
in bacteria was chosen as a negative control. It was analyzed in 10% SDS-PAGE gel and revealed with anti-
hypusine antibodies (lane 3) or anti-GLS2 antibodies (lane 4). Positions of molecular mass markers are shown at 
the left end of panel C. Full-length gels and blots are shown in both panels B and C.
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(Suppl. Tables 1 and 2). Overall, the consolidated sequence coverage from both trypsin and chymotrypsin analy-
sis was 89% (Fig. S8), demonstrating the identity of the GLS2 protein analyzed. With regard to posttranslational 
modifications, LC-MS/MS analysis identified the chymotryptic peptide –KEKKCFPKGVDMMAAL- being mod-
ified with acetylhypusine in the fourth lysine residue (K-336 of the whole GLS2 amino acid sequence) (Fig. 6-A). 
Hypusine (N-ε-(4-amino-2-hydroxybutyl) is an unusual amino acid formed at specific lysine residues after a 
two-step enzymatic process30. Because hypusination is a rare modification, we looked for additional confir-
mation of this posttranslational modification (PTM) found in the GLS2 amino acid sequence. To validate the 
LC-MS data, we used Western blotting employing specific anti-hypusine polyclonal antibodies raised against a 
synthetic hypusine-containing peptide31. Affinity-purified human GLS2 was probed by immunoblot analysis: the 
anti-hypusine antibody recognized a single protein species at the molecular mass (~63 kDa) corresponding to 
the mature GLS2 protein, in four distinct fractions from two independent purifications (Fig. 6-B). A doublet was 
also seen in one fraction, corresponding to the non-processed precursor form of human GLS2 which co-purify 
in some extent with the mature protein (Fig. S7)29. As a positive control, a whole mouse brain and rat prefrontal 
cortex extracts were probed with the anti-hypusine antibody: a protein band of approximately 17 kDa was clearly 
revealed (Fig. 6-C, lanes 1 and 2), corresponding to the known molecular mass of eukaryotic translation initia-
tion factor 5A (eIF5A), the only known protein containing the amino acid hypusine30. As negative controls, we 
included human recombinant GLS256–602 protein expressed in bacteria (Fig. 6-C, lanes 3 and 4), a relevant GLS2 
control because hypusination does not occur in bacterial expression systems, as well as purified recombinant 
Glutaminase-Interacting Protein (GIP) and the human KGA isoform expressed in baculovirus (Fig. S6).
Discussion
Emerging experimental evidences support that GA isozymes exhibit multiple functions32. Elucidation of the 
respective role of each GA isoform may be of profound physiological significance not only in normal conditions, 
but also in pathological states like cancer where GLS and GLS2 isoenzymes seem to play apparently opposing 
roles3. This fact has been clearly demonstrated in recent studies, where inhibition of cancer proliferation and 
reversion of the malignant phenotype were achieved by knocking-down GLS or by upregulation of GLS2 expres-
sion33,34. While overwhelming evidence points to GLS isozymes as oncogenic proteins, underlying metabolic 
reprogramming leading to cancer growth and proliferation in Gln-addicted tumors, the role of GLS2 isozymes in 
tumor biology has not yet been elucidated and needs further clarification35. In the current study, we demonstrated 
that GLS2 can be targeted to the nucleus of cancer cells. The nuclear localization of GLS2 may give us new insights 
to understand non-glutaminolysis functions of this isoenzyme in cancer.
We made use of three distinct experimental approaches for elucidating the nuclear localization of GLS2 pro-
teins in human tumor cells. Our first approach, using immunocytochemistry with isoenzyme-specific antibodies, 
revealed co-localization of GLS2 in both mitochondria and nuclei, although mitochondrial expression was always 
much higher than in cell nuclei under basal conditions. The second one was based on subcellular fractionation 
and immunoblot analysis with the same GA antibodies: nuclear and mitochondrial locations of GLS2 were con-
sistently found. The third approach involved an orthogonal method of validation that does not rely on anti-GLS2 
antibodies: expression of GLS2-tagged proteins in cancer cells. Two different tags, EGFP and c-Myc epitope, were 
employed; in both cases, a fraction of the GLS2-tagged protein was located in cell nuclei, as detected by immuno-
fluorescence or by Western blot with anti-c-Myc specific antibodies. On the other hand, the GA band presented in 
nuclear fractions isolated from human cancer cell lines cannot be ascribed to GLS isoforms by two main reasons: 
first, we always use affinity-purified isoenzyme-specific antibodies for cell immunostaining and Western blots, 
which only recognize GLS or GLS2 isoforms, but not both of them24,25 (Figs. S9 and S10); second, neither KGA 
nor mitochondrial contamination, that might give rise to a GLS band, were present in nuclear extracts employed 
in the analysis. Apart from human cancer cells, we also demonstrated a nuclear location of GLS2 in COS-7 cells 
ectopically expressing the human protein. Consistent with this finding, we previously reported that human GLS2 
protein expressed in Sf9 cells transduced with recombinant baculovirus also localized in both mitochondria and 
nucleus29.
It has been shown that GLS2 expression is downregulated in certain types of cancer like gliomas19, colon22 and 
HCC20–23. Accordingly, the nuclear concentration of GLS2 in HepG2, T98G and SH-SY5Y cancer cells, under 
basal conditions, is very low compared with the mitochondrial pool of this isoform. Therefore, we next tried to 
search for conditions which may enhance the nuclear accumulation of GLS2 and to ascertain whether or not this 
increased nuclear translocation is associated with the reversion of the malignant phenotype and inhibition of cell 
proliferation. Induction of differentiation of HepG2 and SH-SY5Y cells with PMA increases the nuclear translo-
cation of GLS2 in both cell types at early incubation times. Moreover, upregulation of GLS2 was also evident in 
mitochondria; hence, the tumor suppressive effects elicited by GLS2 overexpression might involve mitochondrial 
and nuclear contributions. Of note, GL2 mRNA levels significantly increased in parallel with the terminal dif-
ferentiation of SH-SY5Y cells treated with retinoic acid (RA)36. These authors demonstrated enhanced neurite 
outgrowth after ectopic GLS2 expression in the absence of RA, along with a 40% increase of intracellular ATP 
levels; therefore, they concluded that GLS2 participates in the regulation of neuronal differentiation under the 
transcriptional control of TAp73, a p53 family member36. Further evidences linking GLS2 with cell differentiation 
were recently obtained after the discovery of its regulation by TAp63, another transcription factor belonging to 
the p53 family37. Specifically, GLS2 and TAp63 expression increased during differentiation of primary human 
keratinocytes, whilst depletion of GLS2 inhibited skin differentiation37. Very recently, a nuclear location of GLS 
isoforms was firstly reported in the prostate cancer cell line PC-3, associated with a decreased transcriptional 
activity of peroxisome proliferator-activated receptor γ (PPARγ)38. This role of GLS in transcriptional regulation 
occurs through a direct interaction with PPARγ and independent of its catalytic activity, which further reinforces 
the view of GA as multifaceted moonlighting proteins39.
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Our current work further suggests a causative link between GLS2 expression and tumor suppression. 
Transfection of human GBM cells with GLS2 induces a marked change in the cell’s transcriptome27, leading to 
a more differentiated and less-malignant phenotype characterized by a strong inhibition of cell proliferation27,40 
(Fig. S4). The different phenotypes of these in vitro models were also revealed by studying their growth in adult 
bovine serum, thus avoiding non-physiological levels of cysteine in standard cell culture media which have been 
recently reported to induce an increased reliance on glutamine anaplerosis41. Wild-type and sham-transfected 
T98G GBM cells grow and proliferate under such conditions; however, T98G-GAB cells showed a barred prolif-
eration (Fig. S4-B). Of interest, our results indicate that induction of GLS2 expression in GBM cells also affects 
the regulation of tumor suppressor genes and oncogenes. Notably, active p53 was upregulated in T98G-GAB 
cell nuclei, whilst c-Myc, known to be negatively regulated by p5342, was significantly downregulated in 
T98G-GAB whole cell extracts. Induction of p53 was also noted in the GBM cell line transfected with the vec-
tor alone, whereas p21 was barely detected in the GBM cell lines analyzed. A similar result was obtained in 
PMA-treated SH-SY5Y cells, where GLS2 overexpression was paralleled by marked increases of active p53 and 
the anti-proliferative cyclin-dependent kinase inhibitor p21 in cell nuclei. Thus, increased nuclear transloca-
tion of GLS2 associates with inhibition of proliferation and reversion of the transformed phenotype. This tumor 
suppressor role elicited by GLS2 induction would be mediated, at least in part, by p53-dependent mechanisms. 
Consistent with these results, the p53-dependent GLS2 upregulation and its tumor suppressive role in HCC was 
associated with mitochondrial activation and enhanced antioxidant defense20,21 and, more recently, with inhibi-
tion of Rac1 activation and metastasis suppression38. Notably, the activity of glutathione reductase and levels of 
GSH were significantly higher in T98G-GAB cells than in GLS2-negative T98G wild-type cells43. In this context, 
the unique kinetic properties of GLS2 may represent an important advantage by allowing generation of GSH even 
in a Glu-enriched intracellular milieu, because GLS2 is barely inhibited by the reaction product Glu29, in sharp 
contrast with GLS isoforms5,6.
In relation to the nuclear translocation of GLS2, a perinuclear GLS2-positive staining was clearly revealed 
in HepG2 cells forced to differentiate with PMA. It is well known that the perinuclear region surrounding the 
nucleus may be transitorily enriched in mitochondria, for example to provide energy-rich compound needed 
to satisfy the high-energy requirements of nuclear processes, like nucleocytoplasmic transport of proteins44. 
Therefore, the mitochondrial GLS2 would be translocated to the cell nucleus from this perinuclear mitochon-
drial ring. However, double immunofluorescence labeling and confocal microscopy studies, using anti-VAMP8 
(a vesicle marker) and anti-GLS2 antibodies, suggest that nuclear transport would be vesicle-mediated, because 
the perinuclear zone was highly enriched with VAMP8-containing transport vesicles which strongly overlap with 
the GLS2 staining. In this context, it is noteworthy that VAMP8 was the most upregulated transcript in glioma 
T98G-GAB cells stably transfected with GLS227, while reduced VAMP8 levels have been associated to invasive 
phenotype in breast cancer cells45.
We studied the subnuclear localization of GLS2 in an attempt to get a deep insight into its nuclear role(s). 
Three subnuclear compartments were assessed: nuclear speckles, nucleolus and the nucleoplasm. Although the 
shape of GLS2 immunostaining sometimes appears as condensed granules with a punctate aspect, neither nuclear 
speckles nor nucleoli immunolabeling marks showed a significant overlap with the GLS2 staining, as assessed 
by confocal microscopy analysis and quantitative study of co-localization with Image J. Instead, the GLS2 mark 
was diffusively distributed throughout the nucleoplasm, showing remarkable similarity with the pattern revealed 
for the Jumanji JMJD5 histone demethylase/hydrolase. Therefore, nuclear GLS2 does not seem to be involved in 
functions typically ascribed to speckles and nucleoli, mainly pre-mRNA splicing and pre-rRNA and pre-tRNA 
processing, respectively. However, the cell nucleus is an extremely dynamic organelle; particularly, nuclear pro-
teins and RNAs are constantly in exchange from their particular nuclear compartments with the nucleoplasm46. 
Thus, despite the fact that GLS2 showed a wide distribution in the nucleoplasm, we cannot rule out that it may be 
transitorily associated with some nuclear compartments under specific conditions (cell cycle stage, cell type, the 
presence of stressors, etc.).
An increased nuclear accrual of GLS2 occurred in parallel with the inhibition of proliferation of human cancer 
cells. The antiproliferative response was induced either by differentiation agents (PMA in SH-SY5Y and HepG2 
cells) or by overexpression of GLS2 (T98G-GAB cells). Interestingly, FACS analysis of cell populations consist-
ently detected a stop of the cell cycle at the G2/M stage coincident with the increased nuclear translocation of 
GLS2. In addition, cell cycle arrest at G2/M was paralleled by upregulations of active p53 and cyclin-dependent 
kinase inhibitor p21, whereas oncogene c-Myc was simultaneously downregulated. It is well known that p21 
induction occurs in cells that undergo p53-dependent cell cycle arrest or apoptosis, because the p53-p21 axis is 
a central pathway for cell cycle control and tumor suppression47. Thus, it is tempting to speculate that nuclear 
GLS2 participates in the growth-arrest program preventing unlimited cell proliferation, which may explain why 
certain tumors (e.g. gliomas, hepatomas and lung cancers) showed the opposite behavior: silencing of GLS2 
and upregulation of GLS isoforms to keep active their proliferative program3. Consistent with these findings, 
overexpression of GLS2 in human lung, liver and colon cancer cells induced significant reductions in growth and 
proliferation21,22. In HCC, this effect was greatly mediated by negative regulation of the PI3K/AKT pathway48. 
Furthermore, ectopic expression of GLS2 in liver SMMC-7721 and colon HCT116 cancer cells also induced a 
G2/M arrest22, in accordance with the results here described for human GBM and neuroblastoma cells. This 
G2/M arrest is consistent with the observed accumulation of GLS2, p53 and p21 protein levels, in agreement 
with the functional tumor suppressor role postulated for GLS2 as novel target of the p53 family of tumor suppres-
sors20,21,43. Despite these evidences, GLS2 also suppressed the malignant phenotype of human GBM of different 
tumorigenic potentials and genetic backgrounds, including p53(─) cells27,40. Nevertheless, additional data charac-
terizing the nuclear roles of GLS2 are still needed to definitively substantiate a direct link between cell cycle arrest 
and nuclear translocation of GLS2.
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Cell proliferation is an energetically demanding process and, thereby, tightly coupled with metabolic control28. 
Glutamine is a key nutrient for cell cycle progression and glutaminolysis is required for the G1 to S transition 
along with glycolysis; however, unlike glucose, Gln is the only substrate essential for the progression through S 
phase into cell division, as revealed by the high activity and protein levels of GLS isozymes, which do not decline 
until the G2/M phase is reached49. In sharp contrast, the nuclear accrual of GLS2 in neuroblastoma and glioma 
cells occurs in parallel with cell cycle arrest at the G2/M stage. Interestingly, a completely different response is 
found for cancer cells grown in the absence of Gln or after silencing/inhibition of GLS isoform: cells enter the S 
phase but fail to progress into G2/M49,50. Therefore, Gln deprivation and GLS inhibition arrest cancer cells in S 
phase, while overexpression of GLS2 and exposure to differentiation agents elicit stop at G2/M phase. Thus, the 
anti-proliferative response induced by blocking GLS or by stress due to nutrient (Gln) removal seems to occur by 
different mechanisms to those triggered by GLS2 overexpression. Importantly, GLS2 show anti-oncogenic roles 
independently of its glutaminolysis function in HCC, allowing metastasis suppression through Rac1 activation43 
and repression of the epithelial-mesenchymal transition through the Dicer-miR-34a-Snail axis23.
In chemotherapy, efforts to increase G2/M arrest of cancer cells have also been associated with enhanced 
apoptosis. Interestingly, the generation of reactive oxygen species (ROS) by treatment with oxidizing agents, like 
arsenic trioxide or hydrogen peroxide, synergizes with GLS2 overexpression to suppress malignant properties 
of T98G glioma cells33,40. Of note, GLS2 evoked in these cells lower c-Myc and Bcl-2 protein levels, as well as a 
higher expression of the pro-apoptotic Bid protein, which may explain the marked fall in cell number mediated 
by GLS233,40 (Fig. S4). Thus, glioma cell lines overexpressing GLS2 undergo significant apoptosis after the G2/M 
arrest, a response also found in epithelial and hematological malignancies treated with selective chemothera-
peutic agents that did not affect normal cell counterparts51. In this context, it is noteworthy that stable trans-
fection with GLS2 inhibited cell growth of T98G GBM through downregulation of O6-methylguanine-DNA 
methyltransferase (MGMT) and, thus, sensitized cells to alkylating agents as temozolomide and carmustine40,52. 
Consequently, GLS2 upregulation may facilitate chemotherapeutic intervention in addition to inhibiting glioma 
growth. Alternatively, other strategies targeting GLS isoforms have been successful in cancer cells where glutami-
nolysis becomes essential, as in mutant isocitrate dehydrogenase 1/2 (IDH1/2) GBM subtypes53, or in combined 
therapies devised to counteract the glutaminolysis-based drug resistance response, as reported in T-cell acute 
lymphoblastic leukemia patients treated with anti-Notch1 compounds54. However, no GLS inhibitor has been 
proved successful in the clinic so far. Notably, if GLS2 has location-specific functions independent of glutami-
nolysis in cell nuclei, it could become a promising target. Actually, the pattern of GLS and GLS2 expression dif-
ferentially modulate the clinical outcome of cancers55 and is becoming a useful metabolic signature to diagnose 
responders to GLS cancer therapy56,57.
GLS2 isoform is a protein that shuttles in and out of the nucleus without having a classical nuclear export 
signal or nuclear localization signal required for transportation via exportin/importin pathways24. Therefore, we 
looked for specific posttranslational modifications on the GLS2 protein as a putative selection mechanism for 
nuclear import and/or function. Hypusination of human recombinant GAB was identified by mass spectrome-
try and validated by immunoblot analysis. In eukaryotic cells, this rare posttranslational modification has been 
only found in the eukaryotic translation initiation factor 5A (eIF5A), which plays a key role in cell proliferation 
and survival30. The hypusine residue is essential for interaction of eIF5A with specific nucleotide sequences of 
mRNAs during translation and also for its nucleocytoplasmic shuttling58. The hypusine-modified lysine in the 
GAB primary structure (K-336) is located in an unfolded segment of the protein, a short turn of 9 residues con-
necting two alpha helices in a sequence highly enriched in polar amino acids (KKCFPKGVD), which strongly 
suggest that this hypusinated lysine is exposed to the external medium. Interestingly, the exposed hypusine of 
eIF5A becomes essential for interaction with exportin Xpo4 allowing its nucleocytoplasmic shuttling59. Thus, the 
exposed hypusine residue might be a structural determinant needed for nuclear import of GLS2 through nuclear 
transport receptors or for specific interaction with nucleotides required in a putative transcriptional regulatory 
role, although further experiments will be needed to assess the functional relevance of this PTM in the GLS2 pro-
tein expressed in human cancer cells, as well as the role of the hypusination enzyme machinery in cancer growth 
and proliferation.
conclusion
We demonstrated that GLS2 can be targeted to the cell nucleus in human GBM, neuroblastoma and HCC cells. 
Our studies demonstrated a correlation between nuclear targeting and the antiproliferative response induced by 
GLS2 in human cancer cell lines, but further studies are needed to elucidate whether nuclear GLS2 is causatively 
linked to this response. The results strongly suggest that GLS2 upregulation has tumor suppression activity and 
could help to rewire cellular metabolism toward a normal non-proliferative phenotype, providing a new strategy 
to combat some types of cancer where GLS2 is frequently silenced. Furthermore, expression levels of GLS2 might 
also potentially be used as a prognostic and/or diagnostic factor in some human malignancies.
Methods
cell cultures. Human hepatoblastoma HepG2 cells (European Collection of Cell Cultures, Cambridge, UK) 
were cultured as described previously17. The SH-SY5Y human neuroblastoma cell line (European Collection of 
Cell Cultures, Cambridge, UK) were grown in RPMI (Sigma) medium supplemented with 10% FCS, penicil-
lin (100 U/mL) and streptomycin (100 µg/mL). The T98G and T98G-GAB human glioma cell lines were cul-
tured as described previously27. COS-7 cells were cultured in Dulbecco’s Modified Eagles Medium (DMEM) 
(BioWhittaker) supplemented with 10% FCS (v/v) and same antibiotics mentioned above. Cultures were incu-
bated in a humidified atmosphere at 37 °C with 5% CO2. All cell lines were checked to be free of mycoplasma 
contamination.  The three GBM cell lines (T98G wild-type (T98G-WT), T98G-pcDNA3 sham-transfected and 
T98G-GAB overexpressing GAB isoenzyme) were also grown in adult bovine serum alone, to assess the effects of 
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culturing cells in serum-levels of cystine. Cells (5 × 105) were cultured in 6-well plates following the conditions 
described by Muir et al.41. After one week of culture, cells were counted using a hemocytometer and trypan blue, 
to account only for viable cells.
Expression constructs and cellular transfections. EcoRI and XhoI endonuclease restriction sites flank-
ing the coding region of the human GLS2 cDNA were constructed by PCR using the 2408-bp GLS2 cDNA in 
pGEM-T-Easy as a template60. After double digestion and purification, the insert was cloned into the EcoRI/
XhoI site of pcDNA3 (Invitrogen). COS-7 cells were transfected with the pcDNA3-GLS2 construct using the 
co-precipitation method with calcium phosphate61. Expression of human GLS2 in transduced COS-7 cells was 
analyzed after 48 h. The pEGFP-GLS2 and pCMV-Myc-GLS2 vectors were constructed as follows. The human 
GLS2 cDNA was amplified and flanked by the required endonuclease restriction sites by PCR. After digestion 
and purification, the inserts were cloned into the pEGFP-C1 (XhoI/BamHI) and pCMV-Myc-N (XhoI) vectors 
(Clontech). The orientation and sequence of the GLS2 inserts in all the constructs were confirmed by sequencing.
For transfection with pEGFP-GLS2 and pCMV-Myc-GLS2, SH-SY5Y cells (2 × 105 cells/well) were seeded in 
1 ml of serum-free medium (OPTI-MEM®, Gibco) in a 12-well microtiter plate, and then incubated at 37 °C in a 
5% CO2 incubator overnight to obtain 80–90% confluence. Cells were pre-washed with serum-free OPTI-MEM® 
medium and covered with 1 mL of the same medium. Metafectene PRO (Biontex) was complexed with the 
pEGFP-C1 plasmid at reagent:DNA (v/w) ratio of 4:0.5. Metafectene PRO complex with DNA was added in a vol-
ume of 0.1 mL per well and cells were incubated for 48 h at 37 °C in a 5% CO2 incubator. Cells were washed three 
times with sterile PBS; then, 1 mL of fresh PBS was finally added and cells analyzed by confocal microscopy or 
under UV light in a Nikon microscope (Eclipse E 800). Neuroblastoma SH-SY5Y cells and HepG2 HCC cells were 
also transfected with plasmids pEGFP-GLS2 and pCMV-Myc-GLS2 by using Lipofectamine 3000 (Thermo Fisher 
Scientific) at reagent:DNA ratios (v/w) ranging from 1:3 to 2:3, following the manufacturer’s instructions. A 
pEGFP-24 transfection control plasmid, expressing the GFP protein alone but adding a non-coding spacer nucle-
otide sequence of 671 pb at the C-terminus of GFP, was also prepared in order to yield a similar molecular mass to 
the pEGFP-GLS2 plasmid. COS-7 cells were transfected with pEGFP-24 and pEGFP-GLS2 using FUGENE HD 
(Promega) as transfection reagent. The optimum reagent:DNA ratio (v/w) ratio was 4:0.5. COS-7 cells (5 × 104) 
were seeded in 24-well plates and transfections performed following the manufacturer’s instructions.
preparation of mitochondria and nuclei from human cancer cells. All procedures were carried out 
at 4 °C or in ice. Nuclear extractions of HepG2 and SH-SY5Y cells were done using a Nuclear and Cytoplasmic 
Extraction kit (Thermo Scientific) according to the manufacturer’s instructions. To assess mitochondrial con-
tamination, all nuclear fractions were routinely probed by immunoblot analysis with rabbit polyclonal antibody 
against COX IV (1:3500, Abcam) using cytosolic (mitochondrial) fractions as a positive control. Additionally, 
α-Tubulin (DM1A) Mouse mAb #3873 (1:1000 dilution, Cell Signaling Technology) was included as a cytoplas-
mic marker to further assess that nuclear fractions were not contaminated with cytoplasm.
immunocytochemistry and confocal microscopy. HepG2, SH-SY5Y and T98G cells (3 × 105 cells) 
were seeded in six-well culture plates (3 × 105 cells per well) containing a microscope slide in the bottom. COS-7 
cells were seeded in 24-well culture plates (5 × 104 cells per well) containing a microscope slide in the bottom. 
Cells were fixed and immunostained in the exponential phase of growth (60–72 h after initiating the culture). All 
steps were done at room temperature. The standard protocol for fluorescent labeling of proteins was as follows: 
microscope slides were rinsed briefly with PBS and then fixed with 4% paraformaldehyde (freshly prepared) 
in PBS for 20 min. Following fixation, the slides were rinsed twice with PBS and autofluorescence cells blocked 
with 50 mM NH4Cl in PBS for 10 min. In order to remove the remained NH4Cl, cells were incubated for 10 min 
with 20 mM glycine in PBS. Then, cells were permeabilized for 10 min with 0.1% Triton X-100 (v/v) in PBS 
(0.05% (w/v) sodium deoxycholate in PBS was also included for COS-7 cells). Cells were then blocked with a 
solution of 4% (w/v) bovine serum albumin (BSA Fraction V) and 10% (v/v) fetal calf serum in PBS (Ab dilution 
buffer) for 1 h. The slides were then transferred to a solution of the primary antibody in the same buffer and 
incubated for 1 h. After incubation, the slides were washed 4 × 10 min with PBS and incubated with secondary 
antibody in Ab dilution buffer for 1 h. After 4 × 10 min washes with PBS, the slides were mounted using PBS/
glycerol 1:1 (v/v) with 2% DABCO. Purified anti-GLS2 antibodies were used at a 1:2000 dilution. Experiments 
with pre-immune serum were always run in parallel. Double fluorescence labeling was carried out as described 
elsewhere24,25, using rabbit polyclonal anti-GLS2 antibodies (see Supplemental Figs. S9 and S10) visualized with 
Alexa Fluor 488-conjugated goat anti-rabbit IgG (1:1000, Molecular Probes) and DAPI (10 ng/mL) for 5 min to 
stain nuclei. Affinity-purified rat polyclonal anti-GLS2 antibodies (Fig. S8), which only recognize the cytosolic 
GLS2, were employed to maximize the mitochondrial GLS2 signal in double immunofluorescence labeling exper-
iments with anti-VAMP8 antibodies (marker of transport vesicles) in HepG2 cells treated with PMA. For the rest 
of immunocytochemical studies, affinity-purified rabbit polyclonal anti-GLS2 antibodies were always used. As 
a marker for mitochondria, Alexa Fluor 555-conjugated mouse monoclonal anti-cytochrome c antibody (1:200; 
clone 6H2/B4, isotype IgG1, BD Biosciences) was used for HepG2 cells, and mouse monoclonal anti-cytochrome 
c (A-8) antibody (1:100; Santa Cruz Biotechnology) visualized with Alexa 568 anti-mouse (1:1000, Invitrogen) 
for COS-7 cells. Slides were examined under a Leica-TCS-NT confocal laser microscope using oil immersion 40x 
objective and pinhole = 1. In all cases, immunolabeling was not observed when the primary antibody was omitted 
or pre-immune serum was used instead of primary antibody. Furthermore, the immunolabeling with anti-GLS2 
antibodies could be completely blocked by pre-incubation with the purified protein antigen (Fig. S8). For sub-
nuclear localization of GLS2, double immunofluorescence labeling was performed with anti-GLS2 antibodies 
and the following marker antibodies: rabbit polyclonal anti-JMJD5 (C-terminus) for nucleoplasm (Millipore), 
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dilution 1:200; mouse monoclonal anti-SC35 (phospho) antibody [SC-35] for nuclear speckles (Abcam), dilution 
1:300; and mouse monoclonal anti-Fibrillarin antibody [38F3] for nucleolus (Abcam), dilution 1:300.
cell cycle analysis. SH-SY5Y or T98G cells were seeded in 6-well plates. PMA and DMSO were added 
24 hours after seeding and cells collected 12 or 24 h after treatment. In the case of T98G, T98G-pcDNA3 and 
T98G-GAB cells, they were collected 24 and 48 hours after seeding. After incubation, cells were washed with 
PBS, trypsinized and collected by centrifugation at 285 g for 10 min. Cell pellets were washed again with 500 µl 
of PBS-FBS-HEPES solution (1x PBS, 1% FBS, 10 mM HEPES) and centrifuged at 600 g for 5 min. Cells were 
dispersed in the small volume of PBS and fixed with 1 mL of 70% ice-cold ethanol. The samples were kept at 
−20 °C overnight. After fixation, cells were centrifuged at 600 g for 10 min and washed with the previous buffer 
(procedure repeated twice). Finally, fixed cells were resuspended in 600 µL of staining solution (100 µg/mL RNase 
A and 40 µg/mL propidium iodide in PBS-FBS-HEPES) and incubated in the dark for 30 min at 37 °C. The cell 
cycle distribution was determined using a BD FACSVerse Flow cytometer (BD Biosciences) and analyzed with 
Kaluza software (Beckman Coulter Life Sciences).
Western blotting. Cell extracts and pure GA proteins were analyzed by SDS-PAGE and Western blot-
ting essentially as described60. The blots were developed with the Pierce™ SuperSignal West Pico PLUS 
Chemiluminescent Substrate as recommended by the supplier (Thermo Scientific). The working dilution of 
the anti-GLS2 antibody was 1:1000. The following commercial antibodies were used: phospho-p53 (Ser15) 
Antibody: #9284, Cell signaling technology, dilution 1:1000; purified mouse anti-p21: #556430, BD Pharmingen, 
BD Biosciences, dilution 1:500; anti-c-Myc antibody [Y69]: #ab32072, Abcam, dilution 1:1000; anti-c-Myc tag 
antibody #ab9106, Abcam, dilution 1:4000; anti-TATA binding protein (TBP) antibody [1TBP18], ChIP Grade 
(#ab818): Abcam, dilution 1:1000; mouse monoclonal anti-β-actin antibody MAB1501, clone C4, Merck, dilution 
1:500.
For Western blotting of brain tissues, a mouse (adult male C57BL/6) whole brain extract was prepared as 
outlined before25. Rat (adult male Sprague-Dawley) prefrontal cortex (PFC) was a kind gift of Dr. Gert Lubec. 
Whole protein extract of rat PFC was obtained as described elsewhere62. All animal experiments were carried out 
in accordance with the European Union regulations (Council Directive 86/609/ECC of 24 November 1986) and 
approved by the committee of animal use for research at Malaga University, Spain (RD 1201/2005 of 10 October 
2005).
Heterologous expression of human glutaminases. All the studies with the baculovirus expres-
sion system were done with the Sf9 insect cell line derived from Spodoptera frugiperda. Recombinant bacu-
lovirus for the GLS2 protein was obtained as described before29. Aliquots of the virus stock were maintained 
at −80 °C and 4 °C, following virus titer measurement using the plaque assay technique. For protein produc-
tion, Sf9 cells were cultured in TNM-FH complete media containing 0.35 g/LNaHCO3 and adjusted at pH 
6.0. After filter-sterilization, the media was supplemented with 5% (v/v) bovine fetal serum, 100 IU/mL pen-
icillin, 100 μg/mL streptomycin and 0.25 μg/mL amphotericin. Cells were grown in suspension in 250 or 
500 mL flasks in a metabolic incubator without CO2 exchange at 27 °C. Then, cells were seeded in 140 mm 
culture plates and infected with the recombinant virus at a multiplicity of infection of 1. The cells were fur-
ther incubated at 27 °C in TNM-FH insect cell media containing 5% fetal bovine serum before harvesting at 
4 days post-infection. The cells were stored at −80 °C until purification. The KGA isoform was also expressed 
in baculovirus system. The ORF of human KGA isoenzyme was amplified by PCR using the following prim-
ers: KGABamHI-forward: 5′-CGCCCGGAGGATCCTCCCCTGTTGAG-3′ and KGAHindIII-reverse 
5′-AAGCTTAATGATGATGATGATGATGCTTGTCATCGTCATCCAACAATCCATCAAGATTC-3′ (restric-
tion sites in bold, or stop codon underlined). The reverse primer for KGA contained six codons for histidine 
(indicated in cursive) as well as a recognition site for enteroquinase (shown in bold). The amplified product was 
cloned into the BamHI and HindIII sites of the expression vector pBlueBac4.5 (Invitrogen). Insect cell transfec-
tion, recombinant virus isolation and heterologous expression of human KGA-His in Sf9 insect cells was per-
formed as previously described29.
A GLS2 protein was designed and expressed in bacteria as negative control for hypusine modification of 
human GLS2. The deletion construct GLS256–602 was prepared at the NdeI-NotI sites of pET-28b expression vec-
tor. The induction of E. coli cells was carried out overnight using 1 mM of IPTG at 30 °C. The culture was spun 
down at 4000 g during 20 min and the pellet was conserved at −80 °C. Also, the recombinant human GIP protein 
was expressed in bacteria and purified by affinity chromatography as described before63.
Affinity chromatography of human glutaminases. Sf9 cells (150 × 106) were resuspended in 5 mL of 
buffer I (20 mM Tris, 1 mM EDTA, 250 mM sucrose, pH 8) containing protease inhibitors cocktail (Roche) and 
supplemented with 1% (v/v) TX-100 for 30 min at 4 °C in a rotary shaker. After centrifuging at 100.000 × g for 
10 min the supernatant was applied to the GIP-affinity column. Full details of GIP purification and GLS2 isolation 
by GIP-affinity chromatography have been previously reported29. The affinity resin was packed in small Econo 
Column (BioRad) and equilibrated with buffer I. After passing the supernatant, the column was washed with 
5-column volumes of buffer I and GLS2 was then eluted with a linear NaCl gradient (0–1 M, 10-column volumes) 
in buffer I. Fractions of 0.5 mL were taken and those showing the highest GA specific activities were pooled and 
kept at −20 °C until analysis. Recombinant human KGA was purified by immobilized-metal affinity chromatog-
raphy (IMAC) with a Ni-Sepharose column (Amersham). Infected Sf9 cells (150 × 106 cells) were resuspended 
in buffer A (20 mM Na2HPO4 pH 7.4, 500 mM NaCl, 1% (v/v) TX-100, 10 mM imidazol), containing the Roche 
protease inhibitor cocktail. After incubation for 30 min at 4 °C in a rotary shaker, the extract was centrifuged at 
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100000 g for 10 min and the supernatant was filtered and passed through a 1 mL Ni-Sepharose column equili-
brated in buffer A. The KGA protein was eluted with a linear imidazol gradient (10 mM–500 mM) in buffer A. 
Fractions were analyzed by SDS-PAGE and enzymatic assay.
Finally, bacterial GLS256–602 was also purified by IMAC chromatography. The pellet was resuspended in lysis 
buffer (10 mM K2HPO4, 300 mM KCl, 10 mM imidazole, 10% glycerol, 10 mM Tris-HCl, pH 8, 0.5 mM TCEP) 
containing protease inhibitor cocktail (Roche) and was sonicated as described elsewhere60. Then, the lysed pellets 
were centrifuged at 20000 g for 1 h, and the soluble extract was clarified using a 0,45-µm syringe filter (ClearLine, 
Dutscher). The sample was loaded into a HisTrap column (GE Healthcare). Proteins were sequentially washed 
with 5 column volumes of 75 mM and 100 mM imidazole in buffer 10 mM K2HPO4, 10 mM Tris-HCl, pH 8, 
300 mM KCl, 10% glycerol, 2 mM DTT plus protease inhibitor cocktail. Finally, proteins were eluted with elution 
buffer (20 mM Na2HPO4, 500 mM NaCl, 450 mM imidazole, 10% glycerol, 2 mM DTT).
In-solution proteolytic digestion. Two micrograms of the purified GLS2 protein sample were 
digested with trypsin or chymotrypsin (1:100 w/w) using the filter-aided sample preparation (FASP) as pre-
viously described with minor modifications64,65. All digests were desalted and concentrated with customized 
reversed-phase C18 stage tips66. Lyophilized peptides were reconstituted in 5% formic acid and analyzed by 
LC-MS/MS.
LC–MS/MS analysis using Orbitrap Q-Exactive HF. Mass spectrometry was performed on a hybrid 
linear trap quadrupole Orbitrap Q-Exactive HF spectrometer (ThermoFisher Scientific, Waltham, MA) using the 
Xcalibur version 2.1.0 coupled to an Agilent 1200 HPLC nanoflow system via a nanoelectrospray ion source using 
liquid junction (Proxeon, Odense, Denmark). Solvents for liquid chromatography-mass spectrometry separation 
of the digested samples were as follows: solvent A consisted of 0.4% formic acid in water and solvent B consisted 
of 0.4% formic acid in 70% methanol and 20% isopropanol. From a thermostatic micro-autosampler, 8 μL of the 
tryptic peptide mixture were automatically loaded onto a trap column (Zorbax 300SB-C18 5 μm, 5 × 0.3 mm, 
Agilent) with a binary pump at a flow rate of 45 μL/min. 0.1% TFA was used for loading and washing the pre-
column. After washing, the peptides were eluted by back-flushing onto a 16 cm fused silica analytical column 
with an inner diameter of 50 μm packed with C18 reversed phase material (ReproSil-Pur 120 C18-AQ, 3 μm, Dr. 
Maisch, Ammerbuch-Entringen, Germany). The peptides were eluted from the analytical column with a 27 min 
gradient ranging from 3 to 30% solvent B, followed by a 25 min gradient from 30 to 70% solvent B, and, finally, 
a 7 min gradient from 70 to 100% solvent B at a constant flow rate of 100 nL/min. The analyses were performed 
in a data-dependent acquisition mode using a top 15 CID or HCD method. Dynamic exclusion for selected ions 
was 60 s. A single lock mass at m/z 445.120024 was employed. The maximal ion accumulation time for MS in the 
Orbitrap and MS2 in the linear trap was 500 and 50 ms, respectively. Automatic gain control was used to prevent 
overfilling of the ion traps. For MS and MS2, automatic gain control was set to 106 and 5,000 ions, respectively. 
Peptides were detected in MS mode at a resolution of 60000 (at m/z 400). The threshold for switching from MS to 
MS2 was 2,000 counts. All samples were analyzed as technical, back-to-back replicates.
Raw data were interpreted using Proteome Discoverer 2.1 (Thermo Scientific) and proteins were identified 
using the Mascot search engine (Matrix Science, London, UK). Spectra were matched against the SwissProt/
UniProt human (Homo sapiens) protein database. The MS/MS ion search parameters were the following: the 
number of maximum missed cleavages for trypsin was 2; peptide mass tolerance was ±10 ppm (#13C = 1) and 
fragment mass tolerance was ±0.1 Da; carbamidomethylation of cysteine residues and oxidation of methionine 
residues were determined as fixed and variable modifications, respectively. Additional search using hypusine, 
deoxyhypusine and acetylhypusine modifications on lysine residues was performed. The significant threshold for 
matched peptides was given as p < 0.05. Protein identity was considered as verified if it was present at least with 
two unique peptide sequences.
Statistical analysis. Statistical analysis was performed with GraphPad Prism5 software. Unless indi-
cated otherwise, data are expressed as the mean ± standard deviation (SD) of three independent experiments. 
Experimental data were analyzed using one-way analysis of variance (ANOVA) followed by the Tukey’s test. For 
single comparison between two groups, paired Student’s t test was also used.
Data availability
The datasets used and/or analysed during the current study are available from the corresponding author on 
reasonable request. All data generated or analysed during this study are included in this published article [and its 
supplementary information files].
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